Pindolol use in specific populations: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) Created page with "__NOTOC__ {{Pindolol}} {{CMG}} == <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VISKEN (PINDOLOL) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION..." |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 5: | Line 5: | ||
== | == | ||
====Pregnancy==== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VISKEN (PINDOLOL) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=07fe9cc3-1ef2-420c-b45d-7f1e894b6ef9 | publisher = | date = | accessdate = }}</ref> | {{pcat}} '''B''' | ||
Studies in rats and rabbits exceeding 100 times the maximum recommended human doses, revealed no embryotoxicity or teratogenicity. Since there are no adequate and well-controlled studies in pregnant women, and since animal reproduction studies are not always predictive of human response, Visken® (pindolol), as with any drug, should be employed during pregnancy only if the potential benefit justifies the potential risk to the fetus. | |||
====Nursing Mothers==== | |||
Since Visken® (pindolol) is secreted in human milk, nursing should not be undertaken by mothers receiving the drug. | |||
====Pediatric Use==== | |||
Safety and effectiveness in pediatric patients have not been established.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VISKEN (PINDOLOL) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=07fe9cc3-1ef2-420c-b45d-7f1e894b6ef9 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Revision as of 04:39, 10 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
==
Pregnancy
Studies in rats and rabbits exceeding 100 times the maximum recommended human doses, revealed no embryotoxicity or teratogenicity. Since there are no adequate and well-controlled studies in pregnant women, and since animal reproduction studies are not always predictive of human response, Visken® (pindolol), as with any drug, should be employed during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers
Since Visken® (pindolol) is secreted in human milk, nursing should not be undertaken by mothers receiving the drug.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.[1]
References
Adapted from the FDA Package Insert.